Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 25 Ovarian Neoplasms 19 Neoplasms 12 Fallopian Tube Neoplasms 12 Carcinoma, Hepatocellular 11 Endometrial Neoplasms 7 Neoplasm Metastasis 6 Colonic Neoplasms 6 Carcinoma, Non-Small-Cell Lung 6 Glioblastoma 4 Brain Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 3 Rectal Neoplasms 3 Lung Neoplasms 3 Liver Neoplasms 3 Digestive System Neoplasms 3 Uterine Cervical Neoplasms 2 Sarcoma 2 Recurrence 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Mouth Neoplasms 2 Lymphoid Interstitial Pneumonia 2 Intestinal Neoplasms 2 Gastrointestinal Neoplasms 2 Carcinoma, Renal Cell 2 Carcinoma, Ovarian Epithelial 2 Brenner Tumor 2 Breast Neoplasms 2 Biliary Tract Neoplasms 2 Astrocytoma 2

Interventions

pembrolizumab 1 liposomal doxorubicin 1 Paclitaxel 1 Gemcitabine 1 Carboplatin 1 Bevacizumab 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Cancer Recurrent × Bevacizumab × 30 days × Clear all

NCT06843447 2026-05-26

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡